Artivion announces presentation of late-breaking interim data from amds persevere trial at the 37th european association for cardio-thoracic surgery annual meeting

Interim data demonstrate meaningful reduction of all-cause mortality with amds atlanta , oct. 5, 2023 /prnewswire/ -- artivion, inc. (nyse: aort), a leading cardiac and vascular surgery company focused on aortic disease, today presented interim results from the amds persevere clinical trial in a late-breaking science presentation at the 37th european association for cardio-thoracic surgery (eacts) annual meeting in vienna, austria. dr. fernando fleischman, associate professor of clinical surgery at keck hospital of the university of southern california, presented data from the persevere us ide trial as a late-breaking abstract titled, interim results of amds hybrid prosthesis in acute debakey type i dissection with malperfusion (persevere investigational device exemption study) which includes interim data on 52 study participants at 30-days post-implantation and an additional 8 participants in total follow up (60 total participants).
AORT Ratings Summary
AORT Quant Ranking